ARCA biopharma (FRA:HQ10) 3-Year Book Growth Rate : -19.40% (As of Jun. 2024)

View and export this data going back to 1997. Start your Free Trial

What is ARCA biopharma 3-Year Book Growth Rate?

ARCA biopharma's Book Value per Share for the quarter that ended in Jun. 2024 was €25.03.

During the past 12 months, ARCA biopharma's average Book Value per Share Growth Rate was -17.50% per year. During the past 3 years, the average Book Value per Share Growth Rate was -19.40% per year. During the past 5 years, the average Book Value per Share Growth Rate was -19.10% per year. During the past 10 years, the average Book Value per Share Growth Rate was -35.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of ARCA biopharma was -14.60% per year. The lowest was -53.00% per year. And the median was -35.40% per year.

Competitive Comparison of ARCA biopharma's 3-Year Book Growth Rate

For the Biotechnology subindustry, ARCA biopharma's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ARCA biopharma's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ARCA biopharma's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where ARCA biopharma's 3-Year Book Growth Rate falls into.

Save Embed

;

Save Embed

;

ARCA biopharma 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

ARCA biopharma (FRA:HQ10) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

ARCA biopharma 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of ARCA biopharma's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

ARCA biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ARCA biopharma Inc (FRA:HQ10) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

10170 Church Ranch Way, Suite 100, Westminster, CO, USA, 80021

Website

https://www.arcabio.com

ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.

ARCA biopharma Headlines

No Headlines